Sangamo Therapeutics (NASDAQ:SGMO) Given “Buy” Rating at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Tuesday,Briefing.com Automated Import reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 423.56% from the company’s current price.

Other research analysts have also issued reports about the stock. Barclays increased their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday.

Sangamo Therapeutics Stock Performance

Shares of SGMO traded down $0.09 during mid-day trading on Tuesday, reaching $1.91. 1,990,789 shares of the company were exchanged, compared to its average volume of 6,792,716. The business has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $1.03. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The stock has a market capitalization of $398.52 million, a PE ratio of -2.55 and a beta of 1.15.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The company had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. During the same period in the prior year, the company posted ($0.34) earnings per share. On average, analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several large investors have recently bought and sold shares of SGMO. Meritage Portfolio Management lifted its stake in Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 6,740 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 64,981 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Sangamo Therapeutics by 55.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares during the period. Virtu Financial LLC purchased a new position in Sangamo Therapeutics during the 3rd quarter valued at about $150,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Sangamo Therapeutics in the second quarter valued at $67,000. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.